BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, Younossi I, Ahmed A, Racila A, Henry L. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19:580-589.e5. [PMID: 32531342 DOI: 10.1016/j.cgh.2020.05.064] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Xiao J, Yong JN, Ng CH, Syn N, Lim WH, Tan DJH, Tan EY, Huang D, Wong RC, Chew NWS, Tan EXX, Noureddin M, Siddiqui MS, Muthiah MD. A Meta-Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients. Liver Transpl 2021. [PMID: 34626045 DOI: 10.1002/lt.26331] [Reference Citation Analysis]
2 Hui ST, Wang F, Stappenbeck F, French SW, Magyar CE, Parhami F, Lusis AJ. Oxy210, a novel inhibitor of hedgehog and TGF-β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice. Endocrinol Diabetes Metab 2021;4:e00296. [PMID: 34505423 DOI: 10.1002/edm2.296] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Mathur K, Mazhar A, Patel M, Dakhoul L, Burney H, Liu H, Nephew L, Chalasani N, deLemos A, Gawrieh S. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. Clin Transl Gastroenterol 2021;12:e00420. [PMID: 34730559 DOI: 10.14309/ctg.0000000000000420] [Reference Citation Analysis]
4 Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal NH, Lai M. Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. Hepatol Commun 2021. [PMID: 34970870 DOI: 10.1002/hep4.1841] [Reference Citation Analysis]
5 Nitski O, Azhie A, Qazi-Arisar FA, Wang X, Ma S, Lilly L, Watt KD, Levitsky J, Asrani SK, Lee DS, Rubin BB, Bhat M, Wang B. Long-term mortality risk stratification of liver transplant recipients: real-time application of deep learning algorithms on longitudinal data. Lancet Digit Health 2021;3:e295-305. [PMID: 33858815 DOI: 10.1016/S2589-7500(21)00040-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Metabolism 2021;122:154822. [PMID: 34289945 DOI: 10.1016/j.metabol.2021.154822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM. Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. Hepatol Commun. [DOI: 10.1002/hep4.1765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mazzarelli C, Angrisani D, Viganò R. The Rising Tide of Nonalcoholic Fatty Liver Disease: How Much Time Until the Flood Reaches Our Coast? Clin Gastroenterol Hepatol 2021;19:1299. [PMID: 33248075 DOI: 10.1016/j.cgh.2020.07.025] [Reference Citation Analysis]
9 Ciardullo S, Muraca E, Zerbini F, Manzoni G, Perseghin G. NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. J Clin Endocrinol Metab 2021;106:e2856-65. [PMID: 33878156 DOI: 10.1210/clinem/dgab262] [Reference Citation Analysis]
10 So WZ, Tan FL, Tan DJH, Ng CH, Yong JN, Syn N, Tang ASP, Wong RC, Lin W, Tan EXX, Huang DQ, Dan YY, Chew NWS, Siddiqui MS, Muthiah MD. A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation. Dig Liver Dis 2021:S1590-8658(21)00851-3. [PMID: 34896025 DOI: 10.1016/j.dld.2021.11.011] [Reference Citation Analysis]
11 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2021:gutjnl-2021-324915. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
12 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Pereira ENGDS, Paula DP, Araujo BP, Fonseca MJMD, Diniz MFHS, Daliry A, Griep RH. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol 2021; 27(29): 4913-4928 [PMID: 34447235 DOI: 10.3748/wjg.v27.i29.4913] [Reference Citation Analysis]
14 Bustamante-Bernal MA, Chavez LO, Zuckerman MJ. Endoscopic Bariatric Interventions in Patients with Chronic Liver Disease. Clin Liver Dis 2022;26:139-48. [PMID: 34802660 DOI: 10.1016/j.cld.2021.08.005] [Reference Citation Analysis]
15 Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2021:S0168-8278(21)02177-2. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
16 Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2022;79:180-91. [PMID: 35027111 DOI: 10.1016/j.jacc.2021.11.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Shen B, Wang J, Guo Y, Gu T, Shen Z, Zhou C, Li B, Xu X, Li F, Zhang Q, Cai X, Dong H, Lu L. Dextran Sulfate Sodium Salt-Induced Colitis Aggravates Gut Microbiota Dysbiosis and Liver Injury in Mice With Non-alcoholic Steatohepatitis. Front Microbiol 2021;12:756299. [PMID: 34795650 DOI: 10.3389/fmicb.2021.756299] [Reference Citation Analysis]
18 Rajapaksha IG, Gunarathne LS, Asadi K, Laybutt R, Andrikopoulous S, Alexander IE, Watt MJ, Angus PW, Herath CB. Angiotensin Converting Enzyme‐2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver. Hepatology Communications. [DOI: 10.1002/hep4.1884] [Reference Citation Analysis]
19 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology 2021;161:1030-1042.e8. [PMID: 34416976 DOI: 10.1053/j.gastro.2021.04.074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
20 Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M Sr, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01183-6. [PMID: 34768009 DOI: 10.1016/j.cgh.2021.11.004] [Reference Citation Analysis]
21 Lieber SR, Kim HP, Baldelli L, Nash R, Teal R, Magee G, Desai CS, Loiselle MM, Lee SC, Singal AG, Marrero JA, Barritt AS 4th, Evon DM. Early Survivorship After Liver Transplantation: A Qualitative Study Identifying Challenges in Recovery From the Patient and Caregiver Perspective. Liver Transpl 2021. [PMID: 34529886 DOI: 10.1002/lt.26303] [Reference Citation Analysis]
22 Hassen G, Singh A, Belete G, Jain N, De la Hoz I, Camacho-leon GP, Dargie NK, Carrera KG, Alemu T, Jhaveri S, Solomon N. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. Cureus. [DOI: 10.7759/cureus.25495] [Reference Citation Analysis]
23 Sebastiani G, Patel K, Ratziu V, Feld JJ, Neuschwander-tetri BA, Pinzani M, Petta S, Berzigotti A, Metrakos P, Shoukry N, Brunt EM, Tang A, Cobbold JF, Ekoe J, Seto K, Ghali P, Chevalier S, Anstee QM, Watson H, Bajaj H, Stone J, Swain MG, Ramji A. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). CanLivJ 2022;5:61-90. [DOI: 10.3138/canlivj-2021-0030] [Reference Citation Analysis]
24 Gao F, He Q, Li G, Huang OY, Tang LJ, Wang XD, Targher G, Byrne CD, Luo JW, Zheng MH. A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis. Liver Int 2021. [PMID: 34564946 DOI: 10.1111/liv.15064] [Reference Citation Analysis]
25 Arshad T, Paik JM, Biswas R, Alqahtani SA, Henry L, Younossi ZM. Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. Hepatol Commun 2021;5:1676-88. [PMID: 34558817 DOI: 10.1002/hep4.1760] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Yong JN, Lim WH, Ng CH, Tan DJH, Xiao J, Tay PWL, Lin SY, Syn N, Chew N, Nah B, Dan YY, Huang DQ, Tan EXX, Sanyal AJ, Noureddin M, Siddiqui MS, Muthiah MD. Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01226-X. [PMID: 34801743 DOI: 10.1016/j.cgh.2021.11.014] [Reference Citation Analysis]
27 Younossi ZM, Henry L. Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH). Endocr Pract 2021:S1530-891X(21)01417-8. [PMID: 34952219 DOI: 10.1016/j.eprac.2021.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Choi YS, Beltran TA, Calder SA, Padilla CR, Berry-Cabán CS, Salyer KR. Prevalence of Hepatic Steatosis and Fibrosis in the United States. Metab Syndr Relat Disord 2021. [PMID: 34962146 DOI: 10.1089/met.2021.0111] [Reference Citation Analysis]
29 Stepanova M, Kabbara K, Mohess D, Verma M, Roche‐green A, Alqahtani S, Ong J, Burra P, Younossi ZM. Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients. Hepatology Communications. [DOI: 10.1002/hep4.1915] [Reference Citation Analysis]
30 Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. Hepatol Commun 2021;5:749-59. [PMID: 34027266 DOI: 10.1002/hep4.1673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Deng Y, Ma J, Weng X, Wang Y, Li M, Yang T, Dou Z, Yin Z, Shang J. Kaempferol-3-O-Glucuronide Ameliorates Non-Alcoholic Steatohepatitis in High-Cholesterol-Diet-Induced Larval Zebrafish and HepG2 Cell Models via Regulating Oxidation Stress. Life (Basel) 2021;11:445. [PMID: 34069176 DOI: 10.3390/life11050445] [Reference Citation Analysis]
32 McGlone ER, Ansell TB, Dunsterville C, Song W, Carling D, Tomas A, Bloom SR, Sansom MSP, Tan T, Jones B. Hepatocyte cholesterol content modulates glucagon receptor signalling. Mol Metab 2022;:101530. [PMID: 35718339 DOI: 10.1016/j.molmet.2022.101530] [Reference Citation Analysis]
33 Ren Z, Simons PIHG, Wesselius A, Stehouwer CDA, Brouwers MCGJ. Relationship between NAFLD and coronary artery disease: A Mendelian randomization study. Hepatology 2022. [PMID: 35441719 DOI: 10.1002/hep.32534] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Servin‐rojas M, Olivas‐martinez A, Toapanta‐yanchapaxi L, García‐juárez I. Liver Transplantation in Mexico. Clinical Liver Disease. [DOI: 10.1002/cld.1155] [Reference Citation Analysis]
35 Gor R, Siddiqui NA, Wijeratne Fernando R, Sreekantan Nair A, Illango J, Malik M, Hamid P. Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand. Cureus 2021;13:e14858. [PMID: 34104598 DOI: 10.7759/cureus.14858] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Ciardullo S, Pizzi M, Pizzi P, Oltolini A, Muraca E, Perseghin G. Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States. Obes Surg 2022;32:712-9. [PMID: 34988895 DOI: 10.1007/s11695-021-05885-x] [Reference Citation Analysis]
37 Schwartz S, Lucas J, DeLegge MH. Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice. touchREV Endocrinol 2021;17:112-20. [PMID: 35118457 DOI: 10.17925/EE.2021.17.2.112] [Reference Citation Analysis]
38 Yang X, Jeong K, Yabes JG, Ragni MV. Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct-acting antiviral agents: A national inpatient sample study. Haemophilia 2022. [PMID: 35727998 DOI: 10.1111/hae.14607] [Reference Citation Analysis]
39 Holland CH, Ramirez Flores RO, Myllys M, Hassan R, Edlund K, Hofmann U, Marchan R, Cadenas C, Reinders J, Hoehme S, Seddek AL, Dooley S, Keitel V, Godoy P, Begher-Tibbe B, Trautwein C, Rupp C, Mueller S, Longerich T, Hengstler JG, Saez-Rodriguez J, Ghallab A. Transcriptomic Cross-Species Analysis of Chronic Liver Disease Reveals Consistent Regulation Between Humans and Mice. Hepatol Commun 2021. [PMID: 34558834 DOI: 10.1002/hep4.1797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Lee YT, Wang JJ, Luu M, Noureddin M, Kosari K, Agopian VG, Rich NE, Lu SC, Tseng HR, Nissen NN, Singal AG, Yang JD. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. J Natl Cancer Inst 2021:djab079. [PMID: 34010422 DOI: 10.1093/jnci/djab079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Homkrailas P, Ayoub WS, Martin P, Bunnapradist S. Kidney utilization and outcomes of liver transplant recipients who were listed for kidney after liver transplant after the implementation of safety net policy. Clin Transplant 2021;:e14522. [PMID: 34716954 DOI: 10.1111/ctr.14522] [Reference Citation Analysis]
42 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
43 Han MAT, Yu Q, Tafesh Z, Pyrsopoulos N. Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. J Clin Transl Hepatol 2021;9:71-80. [PMID: 33604257 DOI: 10.14218/JCTH.2020.00082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines 2021;9:1524. [PMID: 34829753 DOI: 10.3390/biomedicines9111524] [Reference Citation Analysis]
45 Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S. Current therapies and new developments in NASH. Gut 2022:gutjnl-2021-326874. [PMID: 35710299 DOI: 10.1136/gutjnl-2021-326874] [Reference Citation Analysis]
46 Subramanian P, Hampe J, Tacke F, Chavakis T. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD). IJMS 2022;23:6996. [DOI: 10.3390/ijms23136996] [Reference Citation Analysis]
47 Musto J, Spengler EK, German MN. Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2021;20:97-107. [DOI: 10.1007/s11901-021-00568-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Romano DN, Mokuolu DC, Katz DJ, DeMaria S Jr. Orthotopic liver transplant in the pregnant recipient: A systematic review of preoperative management and maternal and fetal outcomes. Clin Transplant 2021;35:e14269. [PMID: 33615548 DOI: 10.1111/ctr.14269] [Reference Citation Analysis]
49 Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R, Piercy DL, Seymour KA, Sudan R, Portenier DD, Diehl AM, Coviello AD, Abdelmalek MF. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology 2021;74:1220-33. [PMID: 33724511 DOI: 10.1002/hep.31806] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
50 Younossi ZM, Harring M, Younossi Y, Ong JP, Alqahtani SA, Stepanova M. The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01131-9. [PMID: 34666156 DOI: 10.1016/j.cgh.2021.10.018] [Reference Citation Analysis]
51 Roberts SK, Majeed A. A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Ther Targets 2021;25:889-95. [PMID: 34727818 DOI: 10.1080/14728222.2021.1999416] [Reference Citation Analysis]
52 Gariani K, Jornayvaz FR. Pathophysiology of NASH in endocrine diseases. Endocr Connect 2021;10:R52-65. [PMID: 33449917 DOI: 10.1530/EC-20-0490] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Reference Citation Analysis]
54 Waits SA, Parikh ND. Edging Closer to Commonplace: Assessing the Growth of Living Donor Liver Transplantation in the United States. Liver Transpl 2021;27:959-60. [PMID: 33887807 DOI: 10.1002/lt.26077] [Reference Citation Analysis]
55 Alqahtani SA, Broering DC, Alghamdi SA, Bzeizi KI, Alhusseini N, Alabbad SI, Albenmousa A, Alfaris N, Abaalkhail F, Al-Hamoudi WK. Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease. BMC Gastroenterol 2021;21:245. [PMID: 34074270 DOI: 10.1186/s12876-021-01828-z] [Reference Citation Analysis]
56 Umemura A, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines 2022;10:901. [DOI: 10.3390/biomedicines10040901] [Reference Citation Analysis]
57 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring) 2021;29:1401-12. [PMID: 34365735 DOI: 10.1002/oby.23250] [Reference Citation Analysis]
58 Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 2021;54:880-9. [PMID: 34435378 DOI: 10.1111/apt.16583] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Han MAT, Olivo R, Choi CJ, Pyrsopoulos N. De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation. World J Hepatol 2021; 13(12): 1991-2004 [DOI: 10.4254/wjh.v13.i12.1991] [Reference Citation Analysis]
60 Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules 2022;12:105. [DOI: 10.3390/biom12010105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
61 Stepanova M, Younossi Z. Reply. Clin Gastroenterol Hepatol 2021;19:1299-300. [PMID: 33248088 DOI: 10.1016/j.cgh.2020.07.038] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Younossi ZM, Stepanova M, Lam B, Cable R, Felix S, Jeffers T, Younossi E, Pham H, Srishord M, Austin P, Estep M, Terra K, Escheik C, de Avila L, Golabi P, Kolacevski A, Racila A, Henry L, Gerber L. Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection. Hepatol Commun 2021. [PMID: 34558853 DOI: 10.1002/hep4.1802] [Reference Citation Analysis]
63 Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology 2022. [PMID: 35239194 DOI: 10.1002/hep.32439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
64 Julià H, Benaiges D, Pedro-botet J. Bariatric surgery and non-alcoholic fatty liver disease. Medicina Clínica 2022. [DOI: 10.1016/j.medcli.2021.12.003] [Reference Citation Analysis]
65 Nakamura T, Shirouzu T. Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants. J Clin Med 2021;10:5417. [PMID: 34830699 DOI: 10.3390/jcm10225417] [Reference Citation Analysis]
66 Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol 2021;27:58-69. [PMID: 33291862 DOI: 10.3350/cmh.2020.0189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
67 Kwong AJ, Kim WR. Predicting Survival After Liver Transplantation: A Noble Pursuit or a Fool's Errand? Liver Transpl 2021;27:789-90. [PMID: 33773023 DOI: 10.1002/lt.26057] [Reference Citation Analysis]
68 Waghorn PA, Ferreira DS, Erstad DJ, Rotile NJ, Masia R, Jones CM, Tu C, Sojoodi M, Chen YI, Schlerman F, Wellen J, Martinez RVP, Tanabe KK, Fuchs BC, Caravan P. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. Sci Rep 2021;11:6105. [PMID: 33731798 DOI: 10.1038/s41598-021-85679-4] [Reference Citation Analysis]
69 Zhou H, Tullius SG. Effects of obesity and weight-loss surgery shift the microbiome and impact alloimmune responses. Curr Opin Organ Transplant 2021;26:603-8. [PMID: 34714789 DOI: 10.1097/MOT.0000000000000920] [Reference Citation Analysis]